Target Health Blog

News

Note from client: WOOHOO! Last patient visit (LPV) occurred today!!!

March 27, 2017

,
News

We are always delighted to receive feedback directly from our clients. This recent email made our entire week!

Orphan Drug Development at Target Health Inc.

January 30, 2017

,
News

Target Health is very pleased that it has prepared, submitted and obtained over 20 orphan drug designations, with 3 of these products reaching the market. There were 2 additional orphan programs in which Target Health played a major role.

Transmission of Extensively Drug-Resistant Tuberculosis in South Africa

January 23, 2017

,
News

Drug-resistant tuberculosis threatens recent gains in the treatment of tuberculosis and human immunodeficiency virus (HIV) infection worldwide.

Scientists Provide First Eevidence That Carbamates Can Upset Circadian Rhythms

January 20, 2017

,
News

Synthetic chemicals commonly found in insecticides and garden products bind to the receptors that govern our biological clocks researchers have found.

Ongoing and Completed eSource Programs at Target Health and ICH E6(R2)

January 20, 2017

,
News

Target e*CTR® (eClinical Trial Record) is Target Health’s patented eSource solution fully integrated with Target e*CRF®. A de novo 510(k) was cleared in December 2015 that used direct data entry at the time of the office visit, and an NDA was submitted to FDA with 7 studies which all used Target e*CTR. There were no FDA inspection findings in any of these programs.

First Humans Arrived In North America A Lot Earlier Than Believed

January 17, 2017

,
News

The timing of the first entry of humans into North America across the Bering Strait has now been set back 10,000 years, scientists report.

The Paperless Clinical Trial – New Publication in Applied Clinical Trials

January 16, 2017

,
News

On 4 January 2017, Applied Clinical Trials published an online paper, entitled, “Regulatory Considerations when Designing and Running 21st Century Paperless Clinical Trials.“ The paper is coauthored by Jonathan Helfgott, MS, former the Associate Director for Risk Science at FDA CDER OSI and the main author of FDA’s eSource Guidance, and Jules Mitchel, MBA, PhD, President, Target Health Inc. Jonathan is currently the Coordinator of the Regulatory Science Graduate Program at Johns Hopkins University.

Brain Impairments In Premature Infants May Begin In The Womb

January 10, 2017

,
News

Even before they are born, premature babies may display alterations in the circuitry of their developing brains, according to a first-of-its kind research study.

Cultural Differences May Leave Their Mark On DNA

January 10, 2017

,
News

A UC San Francisco-led study has identified signatures of ethnicity in the genome that appear to reflect an ethnic group’s shared culture and environment, rather than their common genetic ancestry.

Dave Luke, PharmD, FACA, FCCP, Joins Target Health As Sr. Director of Clinical And Scientific Affairs

January 9, 2017

,
News

As part of the continuing growth of Target Health Inc. we welcome Dave Luke, PharmD, FACA, FCCP, as Sr. Director of Clinical and Scientific Affairs. Dave will work closely with all departments at Target Health to provide both clinical, scientific and leadership support for all of our programs.

Contact Target Health

Reach out today and let us know how we can help you!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form